Evidence map›Paper›PMID 40420912›Full record

ArticleInternational journal of nanomedicine2025

Preparation, and ex vivo and in vivo Characterization of Favipiravir-Loaded Aspasomes and Niosomes for Nose-to-Brain Administration.

Maryana Salamah, Balázs Volk, István Lekli, István Bak, Alexandra Gyöngyösi, Gábor Kozma, Zoltán Kónya, Ágnes Szalenkó-Tőkés, Ágnes Kiricsi, László Rovó and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Maryana SalamahInstitute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.ORCID 0000-0003-3833-3233
Balázs VolkDirectorate of Drug Substance Development, Egis Pharmaceuticals Plc., Budapest, Hungary.ORCID 0000-0002-2019-1874
István LekliDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.ORCID 0000-0002-0992-4176
István BakDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.
Alexandra GyöngyösiDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.
Gábor KozmaFaculty of Science and Informatics, Department of Applied & Environmental Chemistry, University of Szeged, Szeged, Hungary.ORCID 0000-0003-2033-0720
Zoltán KónyaFaculty of Science and Informatics, Department of Applied & Environmental Chemistry, University of Szeged, Szeged, Hungary.ORCID 0000-0002-9406-8596
Ágnes Szalenkó-TőkésDepartment of Oto-Rhino-Laryngology and Head-Neck Surgery, University of Szeged, Szeged, Hungary.ORCID 0000-0002-0024-8802
Ágnes KiricsiDepartment of Oto-Rhino-Laryngology and Head-Neck Surgery, University of Szeged, Szeged, Hungary.ORCID 0000-0002-4206-7145
László RovóDepartment of Oto-Rhino-Laryngology and Head-Neck Surgery, University of Szeged, Szeged, Hungary.ORCID 0000-0003-1782-1756
Diána Balogh-WeiserDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Budapest, Hungary.ORCID 0000-0002-9957-1203
István ZupkóInstitute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.ORCID 0000-0003-3243-5300
Ildikó CsókaInstitute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.ORCID 0000-0003-0807-2781
Gábor Katona *Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.ORCID 0000-0003-1564-4813
György Tibor Balogh *Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary.ORCID 0000-0001-8273-1760

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The present study aimed to develop and compare the intranasal applicability of favipiravir-loaded aspasomes (FAV-ASPs) using film hydration method, and favipiravir-loaded niosomes (FAV-NIOs) using ethanol injection method. Methods: The FAV-ASP and FAV-NIO formulations were characterized according to nanoparticulate characteristics (DLS, drug loading, drug encapsulation efficacy, droplet size distribution), drug release and permeability behavior. Results: The optimized FAV-ASP formulation (FAV-ASP8) consisted of FAV, ascorbyl palmitate, Span® 60 and cholesterol (30:25:25:50 w/w) with nano-scale size range (292.06 ± 2.10 nm), narrow polydispersity index (PDI) value (0.36 ± 0.03), adequate zeta potential (-74.73 ± 3.28 mV) and acceptable encapsulation efficiency (55.33 ± 0.41%). The optimized FAV-NIO formulation (FAV-NIO9) contained FAV, Span® 60 and cholesterol (30:30:40 Conclusion: FAV-ASP8 for nose-to-brain delivery system could be a promising formulation to improve FAV bioavailability compared to FAV-NIO9.

Indexed as

AmidesAntiviral AgentsLiposomesPyrazinesAdministration, IntranasalAnimalsBlood-Brain BarrierBrainDrug LiberationMaleNanoparticlesNasal MucosaParticle SizePermeabilityRatsAmidesAntiviral AgentsfavipiravirLiposomesPyrazinesaspasomesex vivo nasal permeabilityfavipiravirin vivo nasal permeabilityniosomesnose-to-brain delivery

Identifiers

PMID40420912
PMCPMC12105672

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.